Quality of life with cemiplimab plus chemotherapy for first-line treatment of advanced non-small cell lung cancer : Patient-reported outcomes from phase 3 EMPOWER-Lung 3
© 2023 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society..
BACKGROUND: EMPOWER-Lung 3, a randomized 2:1 phase 3 trial, showed clinically meaningful and statistically significant overall survival improvement with cemiplimab plus platinum-doublet chemotherapy versus placebo plus chemotherapy for first-line treatment of advanced non-small cell lung cancer. This study evaluated patient-reported outcomes (PROs).
METHODS: PROs were assessed at day 1 (baseline), the start of each treatment cycle (every 3 weeks) for the first six doses, and then at start of every three cycles, using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life-Core 30 (QLQ-C30) and Quality of Life-Lung Cancer Module (QLQ-LC13) questionnaires. Prespecified analyses included a longitudinal mixed-effect model comparing treatment arms and a time to definitive clinically meaningful deterioration (TTD) analysis performed for global health status/quality of life (GHS/QoL) and all scales from the questionnaires. Between-arm TTD comparisons were made using a stratified log-rank test and proportional hazards model.
RESULTS: A total of 312 patients were assigned to receive cemiplimab plus platinum-doublet chemotherapy and 154 to receive placebo plus chemotherapy; 391 (83.9%) were male and the median age was 63.0 years (range, 25-84). For pain symptoms (EORTC QLQ-C30), a statistically significant overall improvement from baseline (-4.98, 95% confidence interval [CI] -8.36 to -1.60, p = .004) and a statistically significant delay in TTD (hazard ratio, 0.39; 95% CI, 0.26-0.60, p < .0001) favoring cemiplimab plus chemotherapy were observed. Statistically significant delays in TTD, all favoring cemiplimab plus chemotherapy, were also observed in functioning and symptom scales. A significant overall improvement from baseline in GHS/QoL was seen for cemiplimab plus chemotherapy compared with nonsignificant overall change from baseline for placebo plus chemotherapy (1.69, 95% CI, 0.20-3.19 vs. 1.08, 95% CI, -1.34 to 3.51; between arms, p = .673). No analyses yielded statistically significant PRO results favoring placebo plus chemotherapy for any QLQ-C30 or QLQ-LC13 scale.
CONCLUSION: Cemiplimab plus chemotherapy resulted in significant overall improvement in pain symptoms and delayed TTD in cancer-related and lung cancer-specific symptoms and functions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:129 |
|---|---|
| Enthalten in: |
Cancer - 129(2023), 14 vom: 15. Juli, Seite 2256-2265 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Makharadze, Tamta [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 23.06.2023 Date Revised 25.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/cncr.34687 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356542564 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356542564 | ||
| 003 | DE-627 | ||
| 005 | 20231226070703.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cncr.34687 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1188.xml |
| 035 | |a (DE-627)NLM356542564 | ||
| 035 | |a (NLM)37151113 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Makharadze, Tamta |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Quality of life with cemiplimab plus chemotherapy for first-line treatment of advanced non-small cell lung cancer |b Patient-reported outcomes from phase 3 EMPOWER-Lung 3 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.06.2023 | ||
| 500 | |a Date Revised 25.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society. | ||
| 520 | |a BACKGROUND: EMPOWER-Lung 3, a randomized 2:1 phase 3 trial, showed clinically meaningful and statistically significant overall survival improvement with cemiplimab plus platinum-doublet chemotherapy versus placebo plus chemotherapy for first-line treatment of advanced non-small cell lung cancer. This study evaluated patient-reported outcomes (PROs) | ||
| 520 | |a METHODS: PROs were assessed at day 1 (baseline), the start of each treatment cycle (every 3 weeks) for the first six doses, and then at start of every three cycles, using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life-Core 30 (QLQ-C30) and Quality of Life-Lung Cancer Module (QLQ-LC13) questionnaires. Prespecified analyses included a longitudinal mixed-effect model comparing treatment arms and a time to definitive clinically meaningful deterioration (TTD) analysis performed for global health status/quality of life (GHS/QoL) and all scales from the questionnaires. Between-arm TTD comparisons were made using a stratified log-rank test and proportional hazards model | ||
| 520 | |a RESULTS: A total of 312 patients were assigned to receive cemiplimab plus platinum-doublet chemotherapy and 154 to receive placebo plus chemotherapy; 391 (83.9%) were male and the median age was 63.0 years (range, 25-84). For pain symptoms (EORTC QLQ-C30), a statistically significant overall improvement from baseline (-4.98, 95% confidence interval [CI] -8.36 to -1.60, p = .004) and a statistically significant delay in TTD (hazard ratio, 0.39; 95% CI, 0.26-0.60, p < .0001) favoring cemiplimab plus chemotherapy were observed. Statistically significant delays in TTD, all favoring cemiplimab plus chemotherapy, were also observed in functioning and symptom scales. A significant overall improvement from baseline in GHS/QoL was seen for cemiplimab plus chemotherapy compared with nonsignificant overall change from baseline for placebo plus chemotherapy (1.69, 95% CI, 0.20-3.19 vs. 1.08, 95% CI, -1.34 to 3.51; between arms, p = .673). No analyses yielded statistically significant PRO results favoring placebo plus chemotherapy for any QLQ-C30 or QLQ-LC13 scale | ||
| 520 | |a CONCLUSION: Cemiplimab plus chemotherapy resulted in significant overall improvement in pain symptoms and delayed TTD in cancer-related and lung cancer-specific symptoms and functions | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a advanced non-small cell lung cancer | |
| 650 | 4 | |a cemiplimab | |
| 650 | 4 | |a non-small cell lung cancer | |
| 650 | 4 | |a patient-reported outcome | |
| 650 | 4 | |a quality of life | |
| 650 | 7 | |a cemiplimab |2 NLM | |
| 650 | 7 | |a 6QVL057INT |2 NLM | |
| 650 | 7 | |a Platinum |2 NLM | |
| 650 | 7 | |a 49DFR088MY |2 NLM | |
| 700 | 1 | |a Quek, Ruben G W |e verfasserin |4 aut | |
| 700 | 1 | |a Melkadze, Tamar |e verfasserin |4 aut | |
| 700 | 1 | |a Gogishvili, Miranda |e verfasserin |4 aut | |
| 700 | 1 | |a Ivanescu, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Giorgadze, Davit |e verfasserin |4 aut | |
| 700 | 1 | |a Dvorkin, Mikhail |e verfasserin |4 aut | |
| 700 | 1 | |a Penkov, Konstantin |e verfasserin |4 aut | |
| 700 | 1 | |a Laktionov, Konstantin |e verfasserin |4 aut | |
| 700 | 1 | |a Nemsadze, Gia |e verfasserin |4 aut | |
| 700 | 1 | |a Nechaeva, Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Rozhkova, Irina |e verfasserin |4 aut | |
| 700 | 1 | |a Kalinka, Ewa |e verfasserin |4 aut | |
| 700 | 1 | |a Gessner, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Moreno-Jaime, Brizio |e verfasserin |4 aut | |
| 700 | 1 | |a Passalacqua, Rodolfo |e verfasserin |4 aut | |
| 700 | 1 | |a Konidaris, Gerasimos |e verfasserin |4 aut | |
| 700 | 1 | |a Rietschel, Petra |e verfasserin |4 aut | |
| 700 | 1 | |a Gullo, Giuseppe |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer |d 1948 |g 129(2023), 14 vom: 15. Juli, Seite 2256-2265 |w (DE-627)NLM000028649 |x 1097-0142 |7 nnns |
| 773 | 1 | 8 | |g volume:129 |g year:2023 |g number:14 |g day:15 |g month:07 |g pages:2256-2265 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cncr.34687 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 129 |j 2023 |e 14 |b 15 |c 07 |h 2256-2265 | ||